TZOFEN Biological Therapeutics was founded in Jerusalem in 2018 to bring cutting-edge, next-generation oncolytic virus technology to help cancer patients everywhere in the world. Driven by our vision, our mission is to develop first-in-class, broadly applicable, product candidates, that are designed to be safe, potent, and systemically deliverable, to treat cancer patients across a variety of tumor types. Supported by scientists, clinicians, and advisors, we are working to advance the field by developing a new generation of optimally designed, oncolytic viruses. At the core of our approach is a cancer-selective gene therapy platform that utilizes modified retrovirus vectors, which are designed to specifically deliver therapeutic genes into the DNA of cancer cells.